Floatz logo

FES F-18

Deep Fibromatosis/Desmoid Tumor

Vanderbilt-Ingram Cancer CenterSmall moleculeEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Deep Fibromatosis/Desmoid Tumor cohort.

Asset / SponsorPhaseRating
Nivolumab
Parabilis Medicines, Inc.
Phase 2B
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Nab-Rapamycin
Sarcoma Oncology Research Center, LLC
Phase 1/2CCC
Trifluridine
Parabilis Medicines, Inc.
Phase 1/2CCC
Fog-001
Parabilis Medicines, Inc.
Phase 1/2CCC

View all 9 →

Same molecule, other indications

FES F-18 is also rated in:

breast cancerDormant
BB
Indicative ·
64 / 100
View asset →
breast carcinomaDormant
B
Indicative ·
60 / 100
View asset →
invasive lobular breast carcinomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →